Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 771

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 771
---
 | ​ | ​ | ​ | ​    | $ |     — | ​ | ​ | ​ | ​                              | $ | 1,084 | ​ | ​ | ​ | ​    | $ |      — | ​ | ​ |
| Maruishi                                     | ​ | ​ | ​                               | ​ |   823 | ​ | ​ | ​ | ​    | ​ |     — | ​ | ​ | ​ | ​                              | ​ | 1,788 | ​ | ​ | ​ | ​    | ​ |      — | ​ | ​ |
| Total other revenue                          | ​ | ​ | ​                               | $ | 1,258 | ​ | ​ | ​ | ​    | $ |     — | ​ | ​ | ​ | ​                              | $ | 2,872 | ​ | ​ | ​ | ​    | $ |      — | ​ | ​ |

Collaborative revenue Beginning in April 2022, the Company began recording its share of the profit generated by KORSUVA injection sales by CSL Vifor to third parties in the United States. Under the license agreements with CSL Vifor, KORSUVA injection net sales are calculated by CSL Vifor which are net of discounts, rebates, and allowances. These amounts include the use of estimates and judgments, which could be adjusted based on actual results in the future. The Company records its share of the net profits from the sales of KORSUVA injection in the United States on a net basis (since the Company is not the primary obligor and does not retain inventory risk) and presents the revenue earned each period as collaborative revenue.

F-22

TABLE OF CONTENTS

#### CARA THERAPEUTICS, INC.

### NOTES TO CONDENSED FINANCIAL STATEMENTS
<div align='center'>**(amounts in thousands, except share and per share data) 
 (unaudited)**</div>

For the three months ended September 30, 2024, CSL Vifor recorded net sales of KORSUVA injection in the United States of approximately $3,004, which resulted in the Company’s profit share amount of $1,298. For the three months ended September 30, 2023, CSL Vifor recorded net sales of approximately $4,400, which resulted in the Company’s profit share amount of $1,932. For the nine months ended September 30, 2024, CSL Vifor recorded net sales of